Menu
30/09/2003
'Next big step' in breast cancer treatment launched
Cancer Research UK scientists will today embark on the next big step towards preventing breast cancer with the launch of a major new trial called IBIS II.
The 10-year study will test a new drug called anastrozole and involve 10,000 healthy women who are at an increased risk of the disease. Anastrozole has already been shown to be the most effective hormone treatment for breast cancer but this will be the first time the drug has been examined as a preventive measure.
Researchers believe that, in post-menopausal women, anastrozole could reduce the risk of breast cancer by more than 50%. Around 30,000 postmenopausal women are diagnosed with the disease in the UK annually, so if successful this intervention could lead to several thousand fewer women developing breast cancer each year.
Both anastrozole and tamoxifen work by interfering with the female hormone oestrogen, which is known to be the most important cause of breast cancer.
The trial follows the successful IBIS-I study which showed that tamoxifen reduces the incidence of breast cancer by a third in women at a higher risk of the disease. During trials of anastrozole as a treatment for early breast cancer, researchers noticed that women taking the drug were around 40% less likely to be diagnosed with a second cancer in the opposite breast compared to women taking tamoxifen.
To be eligible for IBIS II, women must be post-menopausal, not taking HRT and have at least twice the normal risk of breast cancer – for example someone whose mother or sister had breast cancer before the age of 50, or who has two family members with the disease. The trial will compare anastrozole with a placebo and look at how many women develop breast cancer as well as any side effects of the drug.
Although only half of the women on the trial will receive the new drug, all of the women will receive a bone scan, breast screening every 18 months and the best available care and monitoring.
Over 40 centres are now open for recruitment worldwide, including 20 in the UK.
(gmcg)
The 10-year study will test a new drug called anastrozole and involve 10,000 healthy women who are at an increased risk of the disease. Anastrozole has already been shown to be the most effective hormone treatment for breast cancer but this will be the first time the drug has been examined as a preventive measure.
Researchers believe that, in post-menopausal women, anastrozole could reduce the risk of breast cancer by more than 50%. Around 30,000 postmenopausal women are diagnosed with the disease in the UK annually, so if successful this intervention could lead to several thousand fewer women developing breast cancer each year.
Both anastrozole and tamoxifen work by interfering with the female hormone oestrogen, which is known to be the most important cause of breast cancer.
The trial follows the successful IBIS-I study which showed that tamoxifen reduces the incidence of breast cancer by a third in women at a higher risk of the disease. During trials of anastrozole as a treatment for early breast cancer, researchers noticed that women taking the drug were around 40% less likely to be diagnosed with a second cancer in the opposite breast compared to women taking tamoxifen.
To be eligible for IBIS II, women must be post-menopausal, not taking HRT and have at least twice the normal risk of breast cancer – for example someone whose mother or sister had breast cancer before the age of 50, or who has two family members with the disease. The trial will compare anastrozole with a placebo and look at how many women develop breast cancer as well as any side effects of the drug.
Although only half of the women on the trial will receive the new drug, all of the women will receive a bone scan, breast screening every 18 months and the best available care and monitoring.
Over 40 centres are now open for recruitment worldwide, including 20 in the UK.
(gmcg)
Related UK National News Stories
Click here for the latest headlines.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
13 June 2008
'Denied' Cancer Drug Now Available
A costly cancer drug that could have prolonged the life of a patient is now being made widely available in the UK. However, it is too late for charity-fund raiser, Jane Tomlinson, 43, who passed away last September. She was denied the drug, Lapatinib, because her NHS trust would not pay the £6,700 cost.
'Denied' Cancer Drug Now Available
A costly cancer drug that could have prolonged the life of a patient is now being made widely available in the UK. However, it is too late for charity-fund raiser, Jane Tomlinson, 43, who passed away last September. She was denied the drug, Lapatinib, because her NHS trust would not pay the £6,700 cost.
12 August 2010
UK's Breast Cancer Deaths Fall
Population-based breast cancer mortality rates in the UK have dropped steeply in the last two decades - more than in any other major European country - according to a study published on bmj.com. These results challenge claims that survival after breast cancer is worse in the UK than elsewhere in western Europe.
UK's Breast Cancer Deaths Fall
Population-based breast cancer mortality rates in the UK have dropped steeply in the last two decades - more than in any other major European country - according to a study published on bmj.com. These results challenge claims that survival after breast cancer is worse in the UK than elsewhere in western Europe.
01 May 2012
Breast Cancer Can Be Detected Years Before, According To Study
Dr James Flanagan, a Breast Cancer Campaign scientific fellow in the Department of Surgery and Cancer at Imperial College London, has uncovered the first strong evidence that molecular or 'epigenetic' changes in a gene can be associated with breast cancer risk and can be detected many years before breast cancer develops.
Breast Cancer Can Be Detected Years Before, According To Study
Dr James Flanagan, a Breast Cancer Campaign scientific fellow in the Department of Surgery and Cancer at Imperial College London, has uncovered the first strong evidence that molecular or 'epigenetic' changes in a gene can be associated with breast cancer risk and can be detected many years before breast cancer develops.
22 April 2009
Breast Cancer Deaths At Record Low
The number of women dying from breast cancer has fallen to its lowest level since records began, new figures have shown. The data released by Cancer Research UK show that in 2007, 11,990 women in Britain died from breast cancer. In 1941 - the first year statistics were collected - 12,472 women died from the disease.
Breast Cancer Deaths At Record Low
The number of women dying from breast cancer has fallen to its lowest level since records began, new figures have shown. The data released by Cancer Research UK show that in 2007, 11,990 women in Britain died from breast cancer. In 1941 - the first year statistics were collected - 12,472 women died from the disease.
-
Northern Ireland WeatherThis Evening and Tonight:Clear start with a fairly widespread frost developing. Increasing cloud brings occasionally heavy rain overnight, preceded, especially over western hills, briefly by snow. Occasional southeasterly gales, severe near coasts, developing. Minimum temperature -2 °C.
